EPHA2 and neoplasm: By using siRNA knock-down of EphA2, via delivery within MSV (referred to as MSV-EphA2 siRNA in this work), Shen et al have shown a reduction in EphA2 expression and attenuated tumor growth in the HeyA8-MDR-induced mouse model of ovarian cancer12.